Budesonide (Uceris rectal foam) vs Dexamethasone

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: Glucocorticoid receptor · full Ulcerative Colitis pipeline

Budesonide (Uceris rectal foam)

Marketed by Bausch Health

Approved in Ulcerative Colitissmall molecule
Reliable signal

NCT01008423 · Phase 3 · completed

The study was a randomized, triple-blind, placebo-controlled trial with 134 participants receiving budesonide and 147 receiving placebo. Its primary endpoint was a clinical-and-endoscopic remission measure, and the comparison significantly favored budesonide at week 6 (44.0% vs 22.4%, p<0.0001).

No aligned efficacy figure on record for this race.

Dexamethasone

Ownership not recorded

Approved in Ulcerative Colitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBudesonide (Uceris rectal foam)Dexamethasone
Clinical remission (induction)—Not reported—Not reported
Clinical remission (maintenance)—Not reported—Not reported
Clinical response (induction)—Not reported—Not reported
Endoscopic improvement (induction)—Not reported—Not reported
Corticosteroid-free remission (maintenance)—Not reported—Not reported

Clinical remission (induction)

Budesonide (Uceris rectal foam)
—Not reported
Dexamethasone
—Not reported

Clinical remission (maintenance)

Budesonide (Uceris rectal foam)
—Not reported
Dexamethasone
—Not reported

Clinical response (induction)

Budesonide (Uceris rectal foam)
—Not reported
Dexamethasone
—Not reported

Endoscopic improvement (induction)

Budesonide (Uceris rectal foam)
—Not reported
Dexamethasone
—Not reported

Corticosteroid-free remission (maintenance)

Budesonide (Uceris rectal foam)
—Not reported
Dexamethasone
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Budesonide (Uceris rectal foam): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.

Dexamethasone: no structured comparison results are available for Ulcerative Colitis.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Budesonide (Uceris rectal foam)'s landscape · Dexamethasone's landscape